WHO Sounds Concern Over Severe Shortage of Weight-Loss Jabs

Under one in 10 patients that would benefit from obesity jabs such as Wegovy can access them, warns the global health agency as it publishes its inaugural advice on the therapies.

With in excess of 1,000,000,000 people worldwide currently living with obesity, it is urging more widespread and fairer access to this class of drugs.

Based on estimates, more than two billion will be living with obesity by 2030 unless action is taken.

"The new guidelines recognises that excess weight is a chronic disease that can be managed with thorough and continuous care," said WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and distribution challenges are significant obstacles to broad availability to the jabs that can help people shift considerable weight, explains the agency.

Skinny Jab Shortage

Even in the present best projected outlook, the manufacturing of these medications might only reach around 100 million people – under 10% of eligible patients, according to the health organization.

The advice calls on nations and manufacturers to expand availability, via strategies including licensing agreements.

Exclusive production rights on semaglutide – the primary component of a leading brand – is set to lapse in multiple nations in 2026.

How Weight-Loss Jabs Work

These medications mimick a natural hormone to delay gastric emptying, curb appetite and boost feelings of fullness so people consume fewer calories.

Individuals commonly see weight reduction in the initial weeks of beginning the once-weekly jabs.

Research suggests people may see weight return after a year of halting the drug, because their normal appetite resume.

To be overweight or obese elevates your chance for contracting medical conditions, including diabetes, heart disease, brain attack, and specific malignancies.

Obesity affects individuals in every country and was associated with 3.7 million fatalities worldwide in 2024, as per the health agency.